RCT in axSpA (N=200): Digital therapeutic Axia added to stable treatment led to significant improvements in BASDAI (–1.66), BASFI (–1.12), ASQoL (–2.51), with ASAS20/40 responses of 51%/23% vs 9%/3% for usual care. Supports role of DTx in axSpA care. Abstract LB0002 @RheumNow https://t.co/oF6bjIwNIY